TRIXEO® PRESCRIBING INFORMATION
(formoterol fumarate dihydrate/ glycopyrronium/ budesonide)

THIS IS AN ASTRAZENECA INHALER

TRIXEO Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.1

This microsite is intended for UK healthcare professionals only

Prescribing Information and Adverse Events reporting can be found at the bottom of this web page.

This microsite is intended for UK healthcare professionals only

This microsite is intended for UK healthcare professionals only Prescribing Information and Adverse Events reporting can be found at the bottom of this web page.

AEROSPHERE uses an innovative technology that provides effective, consistent drug delivery to the whole lung2,3

The AEROSPHERE Inhaler:

*Of delivered dose

See the AEROSPHERE in action:

Play Video

On demand content to help prevent COPD exacerbations:

Prescribing Information: Eklira ▼ (aclidinium) | TRIXEO (formoterol fumarate dihydrate/ glycopyrronium/ budesonide) | Daxas ▼ (roflumilast) | Bevespi (glycopyrronium/formoterol fumarate dihydrate)

EMBEDDING A PREVENTION MINDSET IN COPD

PROFESSOR JOHN HURST (UNIVERSITY COLLEGE LONDON, GREAT BRITAIN) AND DR VINCENT MCGOVERN (GPWSI, NORTHERN IRELAND)

Approx duration 34 minutes

Play Video

GB-29534

A proactive and preventative approach can change the course of COPD for your patients. Understand the burden of COPD and learn to identify patients at risk of exacerbations in primary care.

REFRAMING COPD MANAGEMENT AT A LOCAL LEVEL

DR MIKE CROOKS (HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST, GREAT BRITAIN) AND NURSE JANE SCULLION (UNIVERSITY OF LEICESTER, GREAT BRITAIN)

Approx duration 34 minutes

Play Video

GB-34028

Understand the steps local healthcare systems can take to help prevent and reduce exacerbations. Review the evidence for triple therapy and recognise how choice and consistency of device can affect the success of COPD treatment.

Interested in future webinars? Check out what’s to come here

The safety profile of Trixeo is consistent with the well-established profile of its components.
The adverse reactions most frequently reported in patients receiving Trixeo are pneumonia (4.6%), headache (2.7%) and urinary
tract infection (2.7%).
Please refer the summary of product characteristics for a full list of adverse events.1
COPD, Chronic Obstructive Pulmonary Disease.

References:

  1. TRIXEO AEROSPHERE 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension. Summary of Product Characteristics. GB Available at https://www.medicines.org.uk/emc/product/12028/smpc. NI Available at https://www.emcmedicines.com/en-gb/northernireland/medicine?id=9f26937e-3415-46a8-b0ce-80d9054dc8f9 &type=smpc .Accessed: September 2022
  2. Taylor G, et al. Eur J Pharm Sci. 2. 2018;111:450–457.
  3. De Backer W, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2673–2684.
  4. Vehring R, et al. Langmuir. 2012;28:15015–15023.
  5. Doty A, et al. AAPS PharmSciTech. 2018;19:837–844.
  6. Lechuga-Ballesteros D, et al. Future Med Chem. 2011;3:1703–1718

LIMITATIONS OF USE
TRIXEO AEROSPHERE is not indicated for the relief of acute bronchospasm.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033. Legal Notice
TBC | September 2022

This website is intended for UK HCPs only. Other UK residents please visit astrazeneca.co.uk
© AstraZeneca 2022. All rights reserved. GB-38021 | DOP: September 2022